ETView Medical Ltd. has successfully combined airway management with continuous direct airway visualization for medical professionals.

VivaSigh ETView’s family of patented, single-use, single- and double-lumen endotracheal tubes, consists of a ventilation tube with an integrated high-resolution system.

ETView has distribution agreements in North America, South America, Europe, Asia,
and Africa.


ProArc Medical Ltd. is an early-stage medical device start-up dedicated to developing innovative, minimally invasive, and clinically effective devices for the field of urology.
The Company’s first product, ClearRing™, is designed to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), or enlarged prostate.


Serpin Pharma is a privately held biotech company developing a family of first-in-class
anti-inflammatory and immune-modulating peptide drugs derived from human alpha-1
antitrypsin. The peptide drugs have broad applications in inflammatory and autoimmune
diseases and represent a superior alternative to current alpha-1 antitrypsin for select
indications. Serpin’s research facilities are located in northern Virginia (United States).

The Trendlines Group creates and develops businesses to improve the human condition.
Seed-stage investors, Trendlines indentifies, invests in, develops, and nurtures innovation-based opportunities in the life sciences (medical devices, biotech, and pharma) and in agritech.

Trendlines invests principally through its platform of Israeli government-licensed incubators,
a unique environment for establishing and nurturing early-stage companies.

Established as a business development consultancy in 1993, Trendlines has the capital, skills, facilities, and staff to identify opportunities, fund, and develop successful business.

Tubular Medical Ltd. is taking an innovative approach to reduce the bioburden (number
of bacteria present on a surface before sterilization) in patients with an endotracheal (ET)
tube. Although an ET tube is vital for safe and effective ventilation, currently available tubes present a significant drawback: Secretions, biofilms, and aerosolized medications that accumulate on the inner surface may cause increased airway resistance, acute tube obstruction, delayed weaning, and Ventilator Associated Pneumonia (VAP).

Tubular Medical introduces a proprietary, fully “peelable” inner surface technology for a simple and highly effective solution to accumulation in ET tubes.

Founded in 2006, Virtual Ports is dedicated to bringing a higher level of performance
to laparoscopic surgery through the use of its proprietary MicroAnchoring™ technology.
Virtual Ports designs and manufactures the only products capable of using existing ports
to retract organs entirely from within the body cavity.

These exceptionally small-profile tools provide secure laparoscopic organ retraction and visualization, and optimize tissue access and visualization, by allowing surgeons to atraumatically retract the organ by lifting and anchoring it to the intra-abdominal wall.


Speech synthesis solutions (translating written text into spoken text) have yet to achieve a level that makes them indistinguishable from human speech.VivoText’s text-to-speech (TTS) engine delivers speech synthesis that is virtually indistinguishable from “real” human voices.
The engine is modeled after a proven technology called Music Objects Recognition (MOR), which was developed by VivoText’s founder.
           Development Stage            Revenue Stage          Public Companies          Holding Company